Affiliation:
1. Division of Pediatric Hematology and Oncology, Department of Pediatrics, University Hospital Carl Gustav Carus, Dresden, Germany;
2. Pediatric Oncology Unit, University Hospital, Poitiers, France
Abstract
AbstractAllogeneic hematopoietic stem cell transplantation (allo-SCT) remains the only proven cure for chronic myeloid leukemia (CML), a rare malignancy in childhood. With the excellent results induced by the tyrosine kinase inhibitor (TKI) imatinib in adults in the last decade, the appropriate management of children with CML has also changed radically, and only a minority are now transplanted as a front-line treatment. Data on pediatric experiences with imatinib in CML from controlled trials remain very limited, but this review of available data describes the role of imatinib in children with CML, addressing: 1) the starting dose; 2) pharmacokinetics in childhood; 3) possible adverse effects, with a focus on the still-growing skeleton; 4) early monitoring of treatment efficacy in an attempt to avoid failure; 5) the timing of allo-SCT in children; and 6) treatment of CML relapse after allo-SCT. Because the characteristics of CML in children seem to overlap extensively with what is described in adult internal medicine, most answers and pediatric algorithms are adapted from the treatment of CML in adults. Today in 2010, allo-SCT in children should be postponed until CML becomes refractory to imatinib. The approach for young patients with suboptimal responses is unclear because data on the efficacy and safety of second-generation TKIs in childhood are almost entirely missing. Other than being included in a formal trial on second-generation TKIs, allo-SCT for patients failing imatinib remains the first choice.
Publisher
American Society of Hematology
Reference63 articles.
1. Ries LAG Melbert D Krapcho M SEER cancer statistics review 2008 Accessed October 6, 2010 Bethesda, MD National Cancer Institute Available from http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008
2. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia;Millot;Pediatrics,2005
3. Correlation of BCR/ABL Transcript Variants with Patients' Characteristics in Childhood Chronic Myeloid Leukaemia;Adler;Eur J Haematol,2008
4. The biology of chronic myeloid leukemia;Faderl;N Engl J Med,1999
5. Major- and/or minor bcr-abl positive chronic myeloid leukemia (CML) in six children with initial presentation as acute lymphoblastic leukemia (ALL) [Abstract];Claviez;Blood,2000
Cited by
84 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献